Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AR 12

Last Updated: 03/28/17

Status: Determined Ineffective for NF2


  • Treatment Information
  • Additional Information

Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.

Treatment Information

Other Names
Pharmaceutical Company Arno Therapeutics
Prescription Information Arno Therapeutics - Drug Description
Expectation Change in Meningioma and Schwannoma in CNS

Inhibitor HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor